Certificate Reference
For continuity with the current catalog, this page links to laboratory documentation for a component or a closely related product. The linked certificate is a reference only and is not represented as the batch-specific COA for FOXO4.
Overview
FOXO4-DRI is a retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53 in senescent cells. It is widely discussed in senescence research because this interaction helps some damaged, senescent cells resist apoptosis.
Research Reference: View compound profile on NIH PubChem
Research Focus
WHAT THIS FORMULA FEATURES
A targeted protein-protein-interaction strategy rather than a general cytotoxic agent. Preclinical research has shown that disrupting FOXO4-p53 can restore p53-driven apoptosis preferentially in senescent cells and alter markers of tissue homeostasis.
EXPECTED RESEARCH READOUTS
Researchers commonly measure senescent-cell viability, p53 localization/signaling, BCL-2 and caspase markers, apoptosis, senescence-associated secretory phenotype markers, and tissue-function readouts in aging models. Selectivity versus non-senescent controls is a critical endpoint.
Research endpoints described above reflect published or model-based scientific observations and are not guaranteed outcomes. This product is strictly for research purposes only. Not approved for human or animal use.
Key Characteristics
MOLECULAR PROFILE
Formula: C228H388N86O64
Weight: 5358 g/mol
CAS: 2460055-10-9
PubChem CID: 167312269
Classification: D-retro-inverso FOXO4 peptide (FOXO4-DRI mapping)
PHYSICAL PROPERTIES
Form: Lyophilized powder
Catalog strengths: 2 mg | 10 mg
Purity specification: ≥99% catalog specification; verify current batch COA
Storage: Store at −20°C (−4°F) for long-term storage or 4°C (39°F) for short-term storage; avoid repeated freeze-thaw cycles.
Testing: Batch documentation should be verified against the current lot before analytical use.
